Beacon Therapeutics

Biotechnology Research • Alachua, Florida, United States • 51-100 Employees

Company overview

Headquarters	14193 NW 119th Terrace, Suite #10, Alachua, Florida 32615, US
Phone number	+14402033987880
Website	beacontx.com
NAICS	541714
Founded	2023
Employees	51-100
Socials

Key Contacts at Beacon Therapeutics

Joan Rooney

Regional Medical Director

Crystal Russo

Director/ Cmc Lead

Robert Maclaren

Scientific Founder And Director

Aojun Li

Director, Biostatistics

Lisa Tuomi

Director, Cinical Development

Attila Nagy

Associate Director Of Technical Development

Amy Christenson

Executive Director, Medical Affairs Lead

Anna Dreismann

Senior Director Of Biology

Nick Piccoli

Senior Director, Clinical Qiality Assurance

Christine A. Parmenter

Director-Analytical Lead

Beacon Therapeutics Email Formats

Beacon Therapeutics uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@beacontx.com), used 56.9% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@beacontx.com	56.9%
{first name}{last name}	johndoe@beacontx.com	36.1%
{last name}{last name}	doedoe@beacontx.com	6.9%

About Beacon Therapeutics

Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP), as well as two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another targeting cone-rod dystrophy (CRD), an inherited retinal disease. Lead development candidate AGTC-501, is a gene therapy program in Phase II clinical trials for the treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss in boys and young men. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. AGTC-501 expresses the full length RPGR protein, thereby addressing the full complement of photoreceptor damage caused by XLRP, including both rod and cone loss. Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space. The Company is supported by funds from Syncona, Forbion, Oxford Science Enterprises, TCGX, Advent Life Sciences and additional investors.

Beacon Therapeutics revenue & valuation

Annual revenue	$2,300
Revenue per employee	$1,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$7,360
Total funding	No funding

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Director

Entry

Manager

Employees by Department

Beacon Therapeutics has 36 employees across 10 departments.

Departments

Number of employees

Funding Data

Beacon Therapeutics has never raised funding before.

Beacon Therapeutics Tech Stack

Discover the technologies and tools that power Beacon Therapeutics's digital infrastructure, from frameworks to analytics platforms.

reCAPTCHA

Security

PWA

Miscellaneous

Redis

Databases

Cloudflare

CDN

Twitter Emoji

Font scripts

PHP

Programming languages

HSTS

Security

WordPress

Blogs

Redis Object Cache

Caching

Yoast SEO

SEO

core-js

JavaScript libraries

Platform.sh

PaaS

Frequently asked questions

Beacon Therapeutics is located in Alachua, Florida, US.

You can reach Beacon Therapeutics at +14402033987880.

Beacon Therapeutics was founded in 2023, making it 3 years old. The company has established itself as a significant player in its industry over this time.

Beacon Therapeutics has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.